Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04385199 · ClinicalTrials.gov registry record · Phase 2
Convalescent Plasma for Patients With COVID-19
A Phase 2 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04385199 is a Phase 2 study that has completed, run by Henry Ford Health System. The registered enrollment target is 30 participants.
The verdict
NCT04385199, a Phase 2 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in patients with COVID-19 respiratory disease.
Interventions
- BIOLOGICAL Convalescent plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-05-04 |
| Est. Completion | 2020-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04385199
The ClinicalTrials.gov registry entry for NCT04385199 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Convalescent plasma is the first listed.
NCT04385199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04385199 about?
NCT04385199 is a clinical study titled "Convalescent Plasma for Patients With COVID-19". Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in patients with COVID-19 respiratory disease.
What is the current status of trial NCT04385199?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-05-04. Estimated completion is 2020-08-01.
What interventions are being tested in trial NCT04385199?
The interventions under investigation include: Convalescent plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04385199?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.